welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that an Independent Data Monitoring Committee (IDMC), following a planned interim futility analysis, recommended continuation of the company’s pivotal Phase 3 trial, CPP FAP-310, evaluating CPP-1X/sulindac for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. For most FAP patients, current medical practice recommends a lifetime of periodic monitoring as well as surgeries (FAP-related events). These FAP-related events include surgical removal of the colon, rectum, surgical pouch, duodenum, and/or high risk adenomas.
expertly curated content related to this topic
-
Ostomy: Diet and Nutrition GuideThis guide provides some basic informati...
-
Effects of Intervention with Sulindac and Inulin/vsl#3 on Mucosal and Luminal Factors in the Pouch of Patients with ...BACKGROUND/AIM: In order to define futu...
-
BCIR for People with a Malfunctioning Kock Pouch or J-Pouchhttps://www.youtube.com/watch?v=mO2eC7ou...
-
Label-Free Global Serum Proteomic Profiling Reveals Novel Celecoxib-Modulated Proteins in Familial Adenomatous Polyp...Celecoxib, a selective inhibitor of cycl...
-
Precancerous Colorectal Lesions (Review)Colorectal cancer (CRC) is a common and ...
-
Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis PatientsThe purpose of this registry is to colle...
-
Prostanoids, Ornithine Decarboxylase, and Polyamines in Primary Chemoprevention of Familial Adenomatous PolyposisBACKGROUND & AIMS : Familial adenoma...